MBR Therapeutics

MBR Therapeutics is a biotechnology company dedicated to overcoming the metabolic barriers that prevent effective cancer treatment. The company focuses on the development of small molecule inhibitors targeting the cystine/glutamate antiporter, specifically the SLC7A11 subunit, to disrupt the redox homeostasis of tumor cells. By inducing oxidative stress within the tumor microenvironment, MBR Therapeutics aims to enhance the sensitivity of aggressive cancers to existing therapies such as radiation and immunotherapy. Their lead candidate, MBR-101, is being advanced for the treatment of high-need oncology indications, including glioblastoma and pancreatic adenocarcinoma.